China SXT Pharmaceuticals (NASDAQ:SXTC) Upgraded to “Sell” at Wall Street Zen

Posted by ABMN Staff on Feb 7th, 2026

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

China SXT Pharmaceuticals Trading Up 6.4%

NASDAQ:SXTC opened at $3.00 on Friday. The firm’s fifty day simple moving average is $136.56 and its 200 day simple moving average is $197.70. China SXT Pharmaceuticals has a twelve month low of $2.63 and a twelve month high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) EPS for the quarter. The firm had revenue of $0.31 million for the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC boosted its holdings in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Free Report) by 107.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,983 shares of the company’s stock after purchasing an additional 15,013 shares during the quarter. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 at the end of the most recent quarter. Institutional investors own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.